Emily Bongard

Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Yongyuth Yuthavong, Bongkoch Tarnchompoo, Tirayut Vilaivan et al. · Proceedings of the National Academy of Sciences · 2012 · 279 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis

Roly Gosling, L. Uiso, Noel E. Sam et al. · American Journal of Respiratory and Critical Care Medicine · 2003 · 155 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial

Christopher Butler, Alike W. van der Velden, Emily Bongard et al. · The Lancet · 2019 · 103 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +5

Variations in presentation, management, and patient outcomes of urinary tract infection: a prospective four-country primary care observational cohort study

Christopher Butler, Nick Francis, Emma Thomas‐Jones et al. · British Journal of General Practice · 2017 · 97 citations · Full text

Life Sciences, Infectious Diseases, Urology +13

Two-Step Synthesis of Achiral Dispiro-1,2,4,5-tetraoxanes with Outstanding Antimalarial Activity, Low Toxicity, and High-Stability Profiles

Gemma L. Ellis, Richard K. Amewu, Sunil Sabbani et al. · Journal of Medicinal Chemistry · 2008 · 83 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14